These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 27067116)

  • 1. Can computed crystal energy landscapes help understand pharmaceutical solids?
    Price SL; Braun DE; Reutzel-Edens SM
    Chem Commun (Camb); 2016 Jun; 52(44):7065-77. PubMed ID: 27067116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potential of computed crystal energy landscapes to aid solid-form development.
    Price SL; Reutzel-Edens SM
    Drug Discov Today; 2016 Jun; 21(6):912-23. PubMed ID: 26851154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. General principles of pharmaceutical solid polymorphism: a supramolecular perspective.
    Rodríguez-Spong B; Price CP; Jayasankar A; Matzger AJ; Rodríguez-Hornedo N
    Adv Drug Deliv Rev; 2004 Feb; 56(3):241-74. PubMed ID: 14962581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Achieving polymorph selectivity in the crystallization of pharmaceutical solids: basic considerations and recent advances.
    Reutzel-Edens SM
    Curr Opin Drug Discov Devel; 2006 Nov; 9(6):806-15. PubMed ID: 17117688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Solid state amorphization of pharmaceuticals.
    Willart JF; Descamps M
    Mol Pharm; 2008; 5(6):905-20. PubMed ID: 18954076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crystal polymorphism in chemical process development.
    Lee AY; Erdemir D; Myerson AS
    Annu Rev Chem Biomol Eng; 2011; 2():259-80. PubMed ID: 22432619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Solid State Concerns During Drug Discovery and Development: Thermodynamic and Kinetic Aspects of Crystal Polymorphism and the Special Cases of Concomitant Polymorphs, Co-Crystals and Glasses.
    Otto DP; De Villiers MM
    Curr Drug Discov Technol; 2017; 14(2):72-105. PubMed ID: 27908255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thermodynamics of water-solid interactions in crystalline and amorphous pharmaceutical materials.
    Sacchetti M
    J Pharm Sci; 2014 Sep; 103(9):2772-2783. PubMed ID: 24327540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virtual Coformer Screening by Crystal Structure Predictions: Crucial Role of Crystallinity in Pharmaceutical Cocrystallization.
    Sun G; Jin Y; Li S; Yang Z; Shi B; Chang C; Abramov YA
    J Phys Chem Lett; 2020 Oct; 11(20):8832-8838. PubMed ID: 32969658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of co-crystals in pharmaceutical design.
    Steed JW
    Trends Pharmacol Sci; 2013 Mar; 34(3):185-93. PubMed ID: 23347591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids.
    Morissette SL; Almarsson O; Peterson ML; Remenar JF; Read MJ; Lemmo AV; Ellis S; Cima MJ; Gardner CR
    Adv Drug Deliv Rev; 2004 Feb; 56(3):275-300. PubMed ID: 14962582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmaceutical cocrystals: an overview.
    Qiao N; Li M; Schlindwein W; Malek N; Davies A; Trappitt G
    Int J Pharm; 2011 Oct; 419(1-2):1-11. PubMed ID: 21827842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The computational prediction of pharmaceutical crystal structures and polymorphism.
    Price SL
    Adv Drug Deliv Rev; 2004 Feb; 56(3):301-19. PubMed ID: 14962583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Solvent Stabilization on Pharmaceutical Crystallization: Investigating Conformational Polymorphism of Probucol Using Combined Solid-State Density Functional Theory, Molecular Dynamics, and Terahertz Spectroscopy.
    Rexrode NR; Orien J; King MD
    J Phys Chem A; 2019 Aug; 123(32):6937-6947. PubMed ID: 31099570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymorph selection: the role of nucleation, crystal growth and molecular modeling.
    Erdemir D; Lee AY; Myerson AS
    Curr Opin Drug Discov Devel; 2007 Nov; 10(6):746-55. PubMed ID: 17987526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphism and crystallization of active pharmaceutical ingredients (APIs).
    Lu J; Rohani S
    Curr Med Chem; 2009; 16(7):884-905. PubMed ID: 19275600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Crystal Structure Informatics for Defining the Conformational Space Needed for Predicting Crystal Structures of Pharmaceutical Molecules.
    Iuzzolino L; Reilly AM; McCabe P; Price SL
    J Chem Theory Comput; 2017 Oct; 13(10):5163-5171. PubMed ID: 28892623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular modeling of hydration in drug design.
    Mancera RL
    Curr Opin Drug Discov Devel; 2007 May; 10(3):275-80. PubMed ID: 17554853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effective volumes of waters of crystallization: non-ionic pharmaceutical systems.
    Glasser L
    Acta Crystallogr B Struct Sci Cryst Eng Mater; 2019 Oct; 75(Pt 5):784-787. PubMed ID: 32830757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful prediction of a model pharmaceutical in the fifth blind test of crystal structure prediction.
    Kazantsev AV; Karamertzanis PG; Adjiman CS; Pantelides CC; Price SL; Galek PT; Day GM; Cruz-Cabeza AJ
    Int J Pharm; 2011 Oct; 418(2):168-78. PubMed ID: 21497184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.